PPARG and non-small cell lung carcinoma: Whereas selective activation of PPARγ in human NSCLC cells leads to fewer metastases and increased survival in nude athymic rats [43], systemic activation of PPARγ in both cancer cells and the tumor microenvironment by pioglitazone leads to increased tumor progression and metastasis in an orthotopic mouse model of lung cancer.